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Palavras-
chave:  
Resistência à quimioterapia, células estaminais cancerígenas, 
glicosilação, sialyl-Tn, Cisplatina 
Resumo:  
 
O cancro de bexiga musculo-invasor (CBMI) encontra-se entre 
os mais mortais dos cancros geniturinários. O tratamento desta 
patologia é feito com regimes quimioterapêuticos baseados em 
Cisplatina, mas que não permitem evitar recidivas ou a progressão 
da doença. As evidências sugerem que a sobre expressão do 
antigénio sialyl-Tn (STn) se associa a casos de CBMI de baixo índice 
proliferativo. Para compreender a função do STn no contexto do 
CBMI analisou-se, por imunohistoquímica, a expressão de STn, Ki-
67 (proliferação) e p53 (agressividade), em 47 casos de cancro de 
bexiga não musculo-invasores (CBNMI) e 120 de CBMI, mas não foi 
encontrada nenhuma relação entre estes marcadores. Contudo, 
verificou-se que o Ki-67 se encontra expresso apenas em áreas 
negativas para STn. Constatou-se também que o STn é expresso em 
quase 80% dos casos de CBMI, podendo ser um indicador eficaz de 
agressividade e progressão tumoral e ter uma função 
preponderante no desenvolvimento da doença. Mais ainda, o STn 
foi considerado um indicador de pior sobrevida em casos de CBMI, 
sugerindo que pode ser usado com marcador de prognóstico. 
Procedeu-se também ao tratamento com Cisplatina (numa dosagem 
de IC50) da linha celular T24, a qual expressa STn, no sentido de 
averiguar a sua relação com a resistência ao fármaco; concluindo-se 
que a expressão de STn não varia com a exposição. Apurou-se 
ainda que as células expostas à Cisplatina sobre expressam um 
painel de genes associado ao fenótipo das células estaminais 
cancerígenas, nomeadamente o LIN28A e o SPARC, que promovem 
a obtenção de pluripotência e o aumento da motilidade celular, 
respetivamente. De uma forma geral, estes resultados reforçam a 
noção que a expressão de STn serve como biomarcador de 
agressividade  e progressão da doença e demonstram pela primeira 
vez a sua relação com a resistência à quimioterapia. São 
necessários mais estudos, com uma amostragem mais alargada, 
para corroborar estes dados preliminares. 
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Keywords: Chemotherapy resistance, cancer stem cells, cancer therapy, 
protein glycosylation, Cisplatin, sialyl-Tn 
Abstract: Muscle-invasive bladder cancer (MIBC) is amongst the most 
common and deadliest genitourinary cancers. The mainstay 
treatment is Cisplatin-based regimens, which are inefficient in 
avoiding tumor relapse and disease dissemination, urging novel 
therapeutics. The modification of cell-surface glycosylation 
patterns is a recognized hallmark of cancer and appears that the 
over-expression of the carbohydrate antigen sialyl-Tn (STn) is 
associated with low proliferating MIBC cases. To further 
understand the role of STn within the bladder cancer pathology, a 
combined analysis of STn, Ki-67 (proliferation) and p53 
(aggressiveness) was performed by immunohistochemistry in 47 
non muscle-invasive bladder cancer (NMIBC) and 120 MIBC cases. 
No relation was found between p53 and Ki-67 expression and STn; 
however Ki-67 was expressed only in STn negative areas of the 
tumor. Yet STn was present in almost 80% of MIBC cases, 
suggesting it is a good indicator of aggressiveness and tumor 
progression and that it might play a preponderant role in tumor 
development. Furthermore, STn was found to be a determinant of 
poorer OS in MIBC cases when compared with NMIBC, suggesting 
that STn might be a good prognostic marker. Moreover, STn 
positive MIBC cell line T24 was exposed to an IC50 dosage of 
Cisplatin to disclose its association with chemoresistance. The STn 
expression did not vary with drug exposure. In addition, 
chemoresistant subpopulations over-expressed a panel of genes 
associated with cancer stem cell phenotype in comparison to the 
parental culture, namely LIN28A and SPARC that relate with 
pluripotency and altered interactions with the tumor stroma 
towards higher motility, respectively. Altogether, these findings 
reinforce the notion that STn expression is a biomarker of 
aggressiveness and progression and highlight for the first time its 
association with chemotherapy resistance. More studies involving 
more patients are warranted to support these preliminary findings. 
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1. Introduction 
Cisplatin (cis-diamminedichloridoplatinum(II); cis-[Pt(NH
3
)
2
(Cl)
2
]) was first 
described by Michele Peyrone in 1845, but its structure was only deduced in 1893 
(Drayton and Catto, 2012; Rosenberg et al., 1969; Stewart, 2007; Trzaska, 2005). 
After several years of investigation Rosenberg realized its potential to induce 
tumour cells death (Rosenberg et al., 1969) and finally in 1978 the drug was 
approved by FDA (Food and Drug Administration) to treat testicular and ovary 
cancer (Trzaska, 2005). Nowadays Cisplatin-based regimens are widely used as 
(neo)adjuvant therapeutics against a wide variety of solid tumours, namely gastric, 
non-small cell lung (NSCL), head and neck, gallbladder, urinary bladder cancer. 
However, Cisplatin treatment is accompanied by severe side effects that include 
renal damage, immune system suppression, gastrointestinal diseases and 
ototoxicity. It may also cause gonadal suppression resulting in amenorrhea or 
azospermia, partial or irreversible infertility and embryo-toxicity. 
Cisplatin is an alquilant agent capable of forming adducts with 
macromolecules, particularly with N7 atoms of DNA purine bases. This originates 
inter and intra-strand DNA cross-links that force cells to mainly stop cell cycle in 
G2/M checkpoint; the inability to repair this damage ultimately leads to 
programmed cell death. However, experimental evidences have revealed that other 
mechanisms such as the production of oxygen reactive species (ROS) and the 
activation of inflammatory pathways may also contribute to induce cell apoptosis 
(Casares et al., 2012). Cisplatin has been proven significantly efficient against 
malignant cells presenting with elevated proliferation rates, which constitutes the 
bulk of the tumour. However, despite a fairly acceptable upfront drug response 
rate, there is a risk of 95% of relapsing for NSCLC patients and a 5-year survival rate 
of only 50% for muscle-invasive bladder cancer (MIBC) (Nadal and Bellmunt, 2014) 
and 15-20%  for ovarian cancer patients (Siddik, 2003); similar scenarios have been 
observed for many other types of cancer. It has been hypothesized that 
chemotherapy may either act as a selective pressure for more aggressive cell 
phenotypes or that less sensible tumour cells may, during the course of treatment, 
acquire mutations that enable them to decoy the drug-induced death.  
Failure of Cisplatin-based regimens is considered both life threatening and a 
major burden to health care systems, as it requires the introduction of more 
expensive second line treatments. Therefore, understanding the mechanisms 
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behind this failure has been a primary goal of many investigators and, in the past 
two decades, some of the events underlying resistance to Cisplatin have been 
disclosed but therapy improvements have been limited. 
Chemotherapy resistance results from a synergism of events that include 
tumour cell extrinsic factors (pharmacokinetic resistance and tumour 
microenvironment) as well as intrinsic factors, namely alterations in drug 
metabolism and drug transport, relative dormancy/slow cell cycle kinetics, over-
efficient DNA repair systems and inhibition of apoptosis. In addition, some 
chemoresistant clones may present self-renewal and pluri/multipotent 
differentiation capability, which are characteristics commonly associated with 
cancer-stem cells (CSC) (Barr et al., 2013; Falso et al., 2012; Hayashi et al., 2013; Yi 
Zhang, Zhi Wang , Jin Yu, Jia zhong Shi, Chu Wang, Wei hua Fu, Zhi wen Chen, 
2012). These cells are regarded responsible for maintaining a small pool of CSC and 
generating more differentiated subpopulations that, during subsequent divisions, 
originate the vast majority of the tumor bulk. The longevity of CSC also makes them 
more susceptible to the accumulation of genetic damage and epigenetic alterations 
that ultimately may enhance more aggressive cell phenotypes (Abubaker et al., 
2013; L. Li et al., 2012). Some subsets of CSC can be found in poorly vascularised 
hypoxic tumour niches, which favours the maintenance of stem-cells characteristics, 
and are consequently exposed to suboptimal drugs concentrations (Cuvillier et al., 
2013; Semenza, 2013a; Trédan et al., 2007). Furthermore, these cells may undergo 
epithelial-to-mesenchymal transitions (EMT) in response to microenvironmental 
stimuli, namely prolonged exposure to low levels of oxygen, and may gain the 
capability to invade and metastasize to regional lymph nodes and distant organs 
(Fazilaty et al., 2013). Altogether, it became consensual that Cisplatin and other 
conventional chemotherapeutic drugs may ultimately contribute to selectively 
maintain a pool of slow dividing or quiescent CSC. These cells are endowed with the 
capability of recapitulating tumour heterogeneity and to undergo EMT and 
Mesenchymal to Epithelial Transition (MET), considered one of the driving forces of 
cancer dissemination. As such, patients would greatly benefit from combined 
therapies including agents capable of selectively eliminating CSC. The ideal drug 
should specifically recognize these cells from the bulk of the tumor mass; include 
means to inhibit resistance mechanisms; and include CSC-killing agents. However, 
the majority of the membrane-bound CSC biomarkers known to date can also be 
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found in normal stem- and non-malignant cells (Richard et al., 2013; J. Wang et al., 
2014), which hampers the development of specific guided therapeutics.  
Alterations in the cell glycosylation pathways also influence the cell behavior in 
a way that favors resistance to chemotherapy. This neglected mechanism of 
resistance has been often associated with an impaired function of membrane-bound 
glycoproteins, such as ATP-binding cassette transporters due to alteration in their 
glycosylation patterns. However, changes in the glycosylation of cell-surface 
proteins has also been shown to influence intra-cellular signaling pathways 
associated with several hallmarks of cancer, in particular resistance to cell death 
(Harduin-Lepers et al., 2012; Zhu et al., 2001). Even though recent publications 
present evidences that mutation in glycogenes may lead to altered glycosylation 
patterns, these events has been frequently associated with microenviromental 
factors that significantly influence the activity and transcriptional regulation of 
glycosyltranferases and sugar nucleotides biosynthesis pathways. Hypoxia, 
responsible by CSC maintenance and multidrug resistance, is among these 
promoters. Therefore, cancer-associated glycans often are surrogate markers of 
chemoresistance and offer potential in the context of CSC identification. 
Envisaging a rationale for an effective therapy, the subsequent chapters 
discuss the main Cisplatin resistance mechanisms known to date, integrating for 
the first time the role of cancer associated glycans. Even though it focuses mainly 
on Cisplatin, it is predictable that many of these strategies may also mediate 
resistance to other drugs. It also provides a comprehensive overview on the impact 
of chemotherapeutic challenge in tumour biology, CSC selection and clinical 
outcome. Moreover, it aims to raise awareness for the fact that microenviromental 
factors responsible for CSC maintenance and drug resistance, namely hypoxia, may 
induce profound alterations in the cell’s glycosylation pathways and ultimately 
create unique glycoprotein variants, a matter with significant implications for the 
development of highly specific guided therapeutics.  
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2. Overview on classical drug resistance mechanisms 
Drug resistance is a multifactorial process to which contributes both tumor 
cell extrinsic and intrinsic factors. Extrinsic factors such as inadequate 
pharmacokinetics of the drugs and abnormal tumor vascularization result in the 
delivery of suboptimal concentrations of the agents to tumor sites. Tumor 
vasculature also originates hypoxic and acidic niches that significantly modulate cell 
function in ways that favor chemoresistance. Similarly, alterations in the 
extracellular matrix architecture as well as stroma cells paracrine signals have been 
found to influence chemotherapy outcome.  In addition, tumor cells may either 
present intrinsic or acquired, developed during the course of treatment, molecular 
mechanism to overcome the chemotherapy challenge. These include i) alterations in 
drug transport and metabolism; ii) over efficient DNA repairing systems; iii) changes 
in cell cycle regulation; iv) and inhibition of apoptosis. Emerging evidences support 
that chemoristance, driven by the above mentioned factors, associates with cancer 
stem cell-like properties as well as the acquisition of EMT phenotypes, thereby 
explaining the high relapse and progression rates presented by first line 
chemotherapy agents.  Based on these considerations, the following sections are 
aimed to illustrate the influence of the main tumour-associated extrinsic and 
intrinsic properties in chemoresistance. 
2.1. Tumor vascularization and hypoxia 
Solid tumors often present tortuous, poorly differentiated and insufficient 
vasculature which results in the delivery of suboptimal concentrations of drugs to 
certain niches (Rundqvist and Johnson, 2013; Trédan et al., 2007). This is also 
responsible by creating an hypoxic environment that significantly influences cell 
metabolism and modulates gene expression, ultimately favoring the 
chemoresistance and the maintenance of CSC (Fazilaty et al., 2013). Furthermore, 
hypoxic signals act as triggers for the expression of genes linked with epithelial-
mesenchymal transition (EMT - addressed in detail in subsequent sections) and drug 
resistant phenotypes (Cuvillier et al., 2013; Fazilaty et al., 2013; Rundqvist and 
Johnson, 2013; Semenza, 2013a, 2013b; Solyanik, 2010; Trédan et al., 2007; van 
der Horst et al., 2012). 
The primary factor mediating the response to hypoxia is the hypoxia-inducible 
factor-1 (HIF-1), an oxygen-sensitive transcriptional activator. HIF-1 consists of a 
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constitutively expressed subunit HIF-1β and an oxygen-regulated subunit HIF-1α (or 
its paralogs HIF-2α and HIF-3α). Biologically, the HIF1α protein is constantly 
synthesized but rapidly degraded by oxygen under non-hypoxic conditions; 
however it becomes resistant to degradation under low oxygen pressure. Once 
translocated to the nucleus it binds to the transcriptional co-activators HIF-1β and 
p300/CBP (Fulda and Debatin, 2007) and activates an array of responses such as 
the over-expression of angiogenic genes (i.e. VEGF, PDGF‐BB and NOS) and growth 
factors (i.e. IGF-II) (Fulda and Debatin, 2007), decreases mitotic and metabolic rates 
and adapts energy requirements to the hypoxic challenge (Marín-Hernández et al., 
2009; Tsai et al., 2013; Yang et al., 2014). In particular, HIF-1 contributes to 
dramatically shift the pattern of intracellular glucose metabolism from aerobic 
cellular respiration to anaerobic glycolysis throughout the transactivation of genes 
encoding glucose transporters (i.e. GLUT-1) and various types of the rate limiting 
enzymes of glycolysis (Yang et al., 2014). It also suppresses the tricarboxylic cycle 
(TCA) via the PDK1 gene encoding for pyruvate dehydrogenase kinase 1, which 
inactivates pyruvate dehydrogenase, responsible for fueling the TCA cycle with 
acetyl-CoA. Moreover, HIF-1has been shown to regulate the expression of 
cytochrome C oxidase (COX) allowing cancer cells to optimize the efficiency of 
respiration at different oxygen levels. Ultimately HIF-1 provides the signaling to 
initiate a cellular reprogramming state that may finish with mitochondrial 
autophagy (Semenza, 2013a, 2013b). By modeling mitochondria activity, HIF-1 
contributes to avoid cell death via apoptotic and necrotic signaling as well as by 
decreasing the levels of ROS.  Furthermore, HIF-1 has also been shown to act as a 
suppressor of apoptosis in cancer cells through the regulation of anti-apoptotic 
target genes. Namely, it antagonizes p53 activation, thereby compromising 
response to chemotherapy in colon, esophagus (Weller, 1998) and testicular germ 
cell tumors (Cavallo et al., 2013). HIF-1 also acts as a regulator of drug efflux 
throughout the activation of the MDR1 gene that encodes for the membrane-
resident P-glycoprotein (P-gp). The P-gp protein belongs to family of ATP-binding 
cassette (ABC) transporters that, even though not responsible by the efflux of 
Cisplatin (Kelland, 2007), is capable of decreasing the intracellular concentration of 
a wide range of other chemotherapy agents (Cuvillier et al., 2013). 
An association between high levels of HIF-1 and Cisplatin resistance has been 
reported for several tumors, including cervix, prostate, the head and neck, and soft 
tissue sarcomas (Cuvillier et al., 2013), under hypoxic conditions. Similarly, HIF-1 
10 
 
is also responsible for the over-expression of another ABC transporter protein, the 
multidrug resistant protein 1 (MRP1) in ovarian (Siddik, 2003) and mucoepidermoid 
carcinomas (Cai et al., 2011). Supporting a role for HIF-1 in chemoresistance, 
elevated levels of HIF-1 have been observed in tumors of different origins and have 
been linked to more resilient tumor cells, poor prognosis and radio- and 
chemotherapy resistance (Cuvillier et al., 2013; Fazilaty et al., 2013; Rundqvist and 
Johnson, 2013). Nevertheless, it should be noticed that, despite the pivotal role of 
HIF-1, other independent mechanisms have also been found to mediate hypoxia 
related chemoresistance. More detailed insights about the role of HIF in 
chemoresistance may be found in excellent recent reviews by Rohwer and Cramer 
(2011) and Monti and Gariboldi (2011). 
2.2. The tumor stroma 
The tumor stroma, mainly formed by the basement membrane, extracellular 
matrix (ECM), cancer-associated fibroblasts (CAFs), immune cells, and vasculature, 
is an evolving entity during the course of disease that may contribute to promote 
growth, invasion, and metastasis (Bremnes et al., 2011a, 2011b; Karnoub et al., 
2007; Tripathi et al., 2012).  Over the recent years, the crosstalk between the 
cancer cells and the tumor stroma has been unveiled (see reviews from Goubran et 
al. (2014) and Munson and Shieh (2014)); nevertheless, the dynamics of cancer cell 
death in response to therapy in the tumor microenvironment has been so far a 
neglected matter. Noteworthy, de Kruijf et al. (2011) have demonstrated that the 
presence of stroma in 574 breast cancer specimens from patients who underwent 
surgery combined, or not, with adjuvant radiotherapy, adjuvant chemotherapy or 
adjuvant endocrine therapy, was an independent prognostic factor for relapse free 
period, particularly in the triple-negative cancer subpopulation (de Kruijf et al., 
2011).    
However, the extracellular matrix components responsible by controlling 
resistance to chemotherapy are still poorly understood. Several in vitro studies have 
demonstrated that the extracellular matrix not only constitutes a physical barrier to 
drug dissemination, but may also exert a protective effect against apoptosis 
induced by various anticancer drugs (Kinugasa et al., 2014; Miyamoto et al., 2004; 
Tiago et al., 2014; Trédan et al., 2007). Miyamoto et al. (2004) has further 
highlighted that the grade of differentiation of pancreatic cells modulates the 
interaction with different ECM macromolecules (fibronectin, collagen I, and collagen 
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IV) and matrix-driven sensitivity to chemotherapeutic drugs, including Cisplatin 
(Miyamoto et al., 2004). The presence of fibronectin, type IV collagen, and laminin 
have also been linked to Cisplatin induced resistance and local recurrence of uveal 
melanomas (Berube et al., 2005). The authors observed that apoptosis was much 
lower after Cisplatin administration in the presence of ECM when compared with cell 
cultured on a non-permissive matrix (Berube et al., 2005). Several studies also point 
out that the over-expression of genes associated with ECM components is 
associated with increased resistance to Cisplatin (Andjilani et al., 2006; Berube et 
al., 2005; Sherman-Baust et al., 2003). Namely, the gene expression profiling of a 
subpopulation of ovarian carcinoma cell line A2780 resistant to Cisplatin as 
revealed a significant up-regulation of the COL6A3 gene, encoding for collagen VI 
(Varma et al., 2005). These findings suggest that chemoresistant cells may 
modulate the composition of the ECM by modulating gene expression within the all 
tumor. The cultivation of Cisplatin-sensitive cells in the presence of collagen VI 
protein enhanced resistance in vitro and in vivo (Sherman-Baust et al., 2003; Xie et 
al., 2014) and immunohistochemistry studies have showed an association between 
collagen VI over-expression, tumor grade  and resistance to chemotherapy 
(Sherman-Baust et al., 2003). Furthermore, ovarian tumors with pronounced 
stromal/mesenchymal gene signatures presented worst outcome when compared to 
non-stroma gene signature groups and those ECM gene signatures are associated 
with chemotherapy resistance. Altogether, these findings suggest that tumor cells 
may directly contribute to remodel their microenvironment to increase survival to 
chemotherapy challenge (Sherman-Baust et al., 2003). Recent studies refer that β1-
integrins play a pivotal role in the ECM-cancer cells interaction underlying resistance 
to chemotherapy. According to Hodkinson et al. (2007) high levels of ECM also 
protected small cell lung cancer cell lines against chemotherapy-induced cell cycle 
arrest and apoptosis by activating β1-integrins and PI3-kinase, which prevents 
caspase-3 activation (Hodkinson et al., 2007). A more recent report in oral 
carcinoma cells lines has shown that adhesion to carcinoma matrix regulates 
Cisplatin-induced proliferation in a pathway involving integrin1, talin and FAK and 
control of NF-kB signaling (Eberle et al., 2011). Based on these observations, it has 
been suggested that the inhibition of ECM-integrin interactions in combination with 
chemotherapy could have positive therapeutic implications (Mahadevan and Von 
Hoff, 2007). Impaired binding of hyluronan to transmembrane receptor CD44 has 
also been shown to influence multiple cell signaling pathways that stimulate tumor 
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cell proliferation, migration, and matrix metalloproteinase secretion, and promote 
CSC properties and Cisplatin resistance.  
Several studies support that alterations in the glycosylation of cell-membrane 
receptors may be a crucial event in the promotion cell-matrix invasion (Madsen et 
al., 2013; Ranjan et al., 2014). Metalloproteinases (MMP) which are responsible for 
the proteolysis of ECM components upon various biological processes including 
carcinogenesis, differentiation, apoptosis, migration and invasion, regulation of 
tumor angiogenesis and immune surveillance may also contribute to modulate 
response to treatment. The balance between MMP and tissue inhibitors of 
metalloproteinases (TIMPs) is crucial for ECM stability and act in a coordinated 
manner to drive cancer progression (Gong et al., 2014). The over-expression of 
TIMP-2, an inhibitor of MMP-2, in ovarian cancer stromal areas has been found 
associated with better response to chemotherapy (Halon et al., 2013). However, in 
vitro assays have shown no significant correlations between resistance to Cisplatin 
and the expression of TIMP-2, suggesting that TIM-2 mediated chemoresistance is 
dependent on the physiological environment. Also, matrix metalloproteinase-7 and -
13 expression associate to Cisplatin resistance in head and neck cancer cell lines 
(Dünne et al., 2005). Again, these observations reinforce that the crosstalk between 
the microenvironment and cancer cell intrinsic characteristics are essential to settle 
on chemotherapy resistance. These findings suggest that disrupting cell-matrix 
interactions may provide ways to block upstream ECM-mediated or downstream 
intracellular signaling cascades and overcome Cisplatin resistance. Taking into 
account encouraging results from studies using matrix modulating agents in 
combination with chemotherapy (Hussain et al., 2012; Kamaraj et al., 2010; Pisano 
et al., 2014), it is now important to fully clarify the role of ECM components in 
platinum resistance to design rational therapeutic approaches.  
Stromal changes also include the development of CAFs that play a crucial role 
in disease. During recent years, the crosstalk between the cancer cells and CAFs has 
been unveiled and comprehensively reviewed by several authors (Brennen et al., 
2012; Liu et al., 2012; Puré, 2009). CAFs have been found to directly drive cancer 
development through a multiple mechanisms, which include the promotion of 
angiogenesis and the proliferation, invasion and inhibition of apoptosis in cancer 
cells (Brennen et al., 2012; Hale et al., 2013). The expression and secretion of 
numerous growth factors, cytokines, proteases, and extracellular matrix proteins, 
such as SDF-1, FGF2, VEGF, TGF-, HGF, tenascin-c, LOX, and the MMPs are among 
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the key molecules mediating these events. The growth factors and other proteins 
produced by activated fibroblasts not only act on cancer cells but also on other 
cellular elements of the stroma, including adipocytes, inflammatory and immune 
cells, as well as on the remodeling of the ECM, creating intricate feedback loops 
mediated by paracrine and autocrine signals that drive CAFs formation, disease 
progression and dissemination (Brennen et al., 2012; Hale et al., 2013). 
Nevertheless, only limited data on the response of CAFs to chemotherapy and their 
potential impact on therapy outcome are available. Namely, Sonnenberg et al. 
(2008) addressed the influence of CAFs in lung and breast tumors and primary 
cultures and pointed out that, similar to cancer cells, the sensitivity of CAFs to 
Cisplatin is highly variable and dependent on the cancer type as well as the 
microenvironment. Nevertheless, studies have demonstrated that the presence of 
CAFs contributes to the decreased response to chemotherapy in prostate (Franco 
and Hayward, 2012) , renal cell and breast cancers (Mink et al., 2010). Furthermore, 
strategies targeting CAFs molecules have proven capable of improve response to 
chemotherapy (Elenbaas and Weinberg, 2001; Loeffler et al., 2006), reinforcing a 
role for these cells in treatment outcome. Also, a recent systematic review by Hale 
et al. (2013) has highlighted that the available literature on supports stroma-derived 
biomarkers, with emphasis on molecules produced by CAFs, as useful biological 
markers to predict response to therapy.  
Several studies support as well that CSC, known for their relative resistance to 
chemotherapy, also receive critical maintenance cues from supportive stromal 
elements, including CAFs (Ishikawa et al., 2014; Vannucci, 2014). Namely, the 
interplays between CSC and CAFs towards increased chemoresistance and CSC self-
renewal and invasion,  have been recently demonstrated for colorectal cancer by 
Lotti et al. (2013). According to this study, chemotherapy induces the remodeling of 
the tumor microenvironment to support cellular hierarchy through secreted factors 
that include IL-17A. 
Overall, there is a growing amount of data supporting that stromal 
components promote chemoresistance and therefore should be critically evaluated 
for an optimal therapeutic development. Furthermore, the incorporation of 
therapeutics targeting the tumor microenvironment may be determinant for 
disrupting CSC mechanisms. 
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2.3. Alterations in intracellular drug concentration 
Cisplatin-resistant cells often present reduced intracellular platinum 
accumulation when compared to non-resistant cells following drug exposure. This 
may result either from reduced uptake, increased drug export or intracellular 
sequestration. 
2.3.1. Cisplatin uptake 
Cisplatin uptake is mainly mediated by high affinity copper transporter protein 
1 (hCtr1) and its down-regulation has been associated with resistance to platinum-
based drugs in vitro (Larson et al., 2009; Shang et al., 2013; Sinani et al., 2007) and 
in vivo (Larson et al., 2009; Skvortsov et al., 2012; C.-Y. Tsai et al., 2014).An 
association between hCtr1 rs7851395 and rs12686377 polymorphisms and 
platinum resistance in NSCLC patients has also been described (Xu et al., 2012). 
Nevertheless, more clinical studies are required to determine the prognostic value 
of hCtr1 and its genetic variants in the context of Cisplatin treatment. The hCtr1 
protein is responsible for regulating intracellular copper homeostasis and hCtr1 
expression via a homeostatic feedback loop (Howell et al., 2010). The exposure to 
copper-chelating agents has proven to increase the expression of hCtr1 and 
sensitize tumor cells to platinum (Lu, 2010). Furthermore, a pilot clinical trial has 
shown that the administration of copper-lowering agent was able to, at least 
partially, reverse platinum resistance in patients with platinum-resistant high-grade 
epithelial ovarian cancer (Fu et al., 2012). Altogether, these observations reinforce a 
role for hCtr1 protein in chemoresistance and support larger studies to assess the 
efficacy of this approach for treating platinum resistant cancers. Other transporters, 
namely Solute Carrier Family 22 Members 1 and 2 (Yonezawa et al., 2006) and 
Multidrug resistance protein 6 (Nomura et al., 2005) have also been implicated in 
Cisplatin uptake; nevertheless more reports are also required to fully disclose its 
role in chemoresistance as well as their biomarker potential.   
2.3.2. Cisplatin efflux 
The efflux of platinum-based drugs is mainly mediated by Transporting P-type 
Adenosine Triphosphatases ATP7A and ATP7B (Drayton and Catto, 2012; Stewart, 
2007; Tadini-Buoninsegni et al., 2014). Not surprisingly, the over-expression of 
these cell surface proteins have been implicated in Cisplatin resistance and poor 
patient survival in several types of cancer (Aida et al., 2005; Stewart, 2007; Stewart 
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et al., 1995). Silencing of ATP7A in Cisplatin resistant cells restored drug sensitivity 
to a certain scale, suggesting this may also be a strategy to sensitize cancer cells to 
this compound (Z. Li et al., 2012).  
Resistance to Cisplatin has also been associated with the over-expression of 
multidrug resistance-associated proteins (MRPs) 1, 2, 3 and 5, members of the 
superfamily of ATP-binding cassette (ABC) (Kelland, 2007; Solyanik, 2010). In 
particular, MRP2 was shown to be upregulated in a variety of Cisplatin-resistant 
derivatives of human cancer cell lines, where its expression correlated with 
decreased Cisplatin accumulation (Taniguchi et al., 1996). Furthermore, reduction 
of MRP2 expression using ribosomes shown to restore Cisplatin sensitivity in 
Cisplatin resistant adrenocortical carcinoma and melanoma cell lines (Nakamura et 
al., 2005) reinforcing a role for this molecule in Cisplatin resistance. Nevertheless, it 
has been demonstrated that Cisplatin is not a substrate for MRP proteins and that 
its ability to transport the drug across the cell membrane requires the formation of 
glutathione or metallothionein-Cisplatin conjugates (discussed in detail in the 
following section) (Chen et al., 1998; Kelland, 2007; Wen et al., 2014; Y et al., 
1999). 
2.3.3. Detoxification by intracellular molecules 
Even though purine bases of DNA are the main target of Cisplatin, a vast 
majority of Cisplatin molecules will react with other ligands before having the 
chance of reaching the nucleus. In particular, Cisplatin shows much higher affinity 
to thiol groups when compared to nitrogen, making intracellular detoxification by 
these functional groups one of the main mechanisms of Cisplatin scavenging 
(Galluzzi et al., 2014, 2011). As such, resistance to Cisplatin has been associated 
with the over-expression of metallothioneins, a class of low-molecular weight 
cysteine-rich proteins that promote intracellular homeostasis of physiological 
metals, which provide protection against metal toxicity and oxidative stress (Knipp, 
2009). This has been observed both in different cancer models (Gansukh et al., 
2013; Peng et al., 2012), as well as in bladder (Siu et al., 1998; Wülfing et al., 
2007), colorectal (Hishikawa et al., 2001), esophageal (Hishikawa et al., 1997) and 
breast carcinomas (Bay et al., 2006; Lai et al., 2011), among others.  
Glutathione (GSH), a thiol containing tripeptide (Glu-Cys-Gly) highly expressed 
in mammalian cells also plays a key role in Cisplatin scavenging. Cisplatin-GSH 
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conjugates are catalyzed by the action of glutathione-S-transferases, namely GSTP1-
1, that link the reduced form of glutathione (GSH) to xenobiotic substrates for the 
purpose of detoxification (Galluzzi et al., 2014). Increased expression of enzymes 
involved in GSH synthesis and conjugation have been implicated in the generation 
of Cisplatin resistance (Chen and Kuo, 2010; Galluzzi et al., 2014; Wu et al., 2013). 
Also, elevated levels of glutamate/cysteine transport system (system Xc) were linked 
with higher intracellular levels of GSH and resistance to Cisplatin  (Okuno et al., 
2003). The efflux of GSH-Cisplatin conjugates from cells is an ATP-dependent 
process mediated by integral membrane glycoproteins belonging to the MRP family 
(Keppler, 1999; Oguri et al., 1998). Furthermore, MRPs are functionally over-
expressed in Cisplatin-resistant human cancer cells in which the cellular GSH level 
was substantially enhanced (Demeule et al., 1999; Guminski et al., 2006; Ishikawa 
et al., 1994), suggesting that GSH and MRP proteins work in a concert manner.  
2.4. Alterations of DNA repairing systems 
Several DNA repair pathways interplay to maintain accurate DNA replication, 
genomic integrity and normal cell functioning. These include i) nucleotide excision 
repair (NER); ii) base excision repair (BER); iii) homologous recombination repair 
(HR); iv) Mismatch repair (MMR); v) Non-Homologous DNA End-Joining repair (NHEJ); 
and vi) O6- alkylguanine DNA alkyl transferase (AGT) repair systems. Efficient DNA 
repairing systems are considered essential for the maintenance and longevity of 
stem cell phenotypes. However, when over-efficient these repairing systems play a 
key role in the resistance to damage induced by cytotoxic drugs.   
In particular, several reports describe associations between the alterations in 
the XPF-ERCC1 protein complex of the NER system and platinum-based treatment 
outcome. This complex is a structure-specific endonuclease essential for DNA 
damage repair, which includes DNA interstrand crosslink and double-strand break 
repair. The impossibility to replace damaged nucleotide sequences promotes 
downstream activation of the BAX mitochondrial membrane protein, which is 
responsible for inducing apoptosis (Fuss and Cooper, 2006; Igney and Krammer, 
2002). An over-expression of members of this complex has been found to promote 
resistance to platinum-based compounds in vitro (Arora et al., 2010; Hatch et al., 
2014), most likely due to an over-efficient DNA repair system. In agreement with 
these observations, retrospective studies involving patient’s histological samples 
have highlighted an association between the over-expression of ERCC1, resistance 
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to chemotherapy and poor outcome in squamous cell head and neck and bladder 
carcinomas (Bauman et al., 2013). A recent clinical trial has also demonstrated that 
elevated expression of the ERCC1 gene is an independent prognostic factor for 
overall survival in first line treatment of advanced gastric cancer (D. H. Smith et al., 
2013).  Furthermore, a phase II trial showed that single nucleotide polymorphisms 
of ERCC1 gene (118T/C and 8092C/A) could be used to determine the response of 
non-small cell lung cancer patients to Cisplatin (Mazzoni et al., 2013); another 
study has demonstrated that the 8092C/A polymorphism could be used as an 
independent predictive biomarker of better response in esophageal cancer patients 
treated with Cisplatin-based regimens (Tse et al., 2008). An enhanced expression of 
ERCC1 has also been observed in esophageal (Zhao et al., 2014) and ovarian 
(Abubaker et al., 2013) platinum resistant cancer-stem cell subpopulations.    
Cisplatin resistance has also been associated with deregulations of Mismatch 
Repair system associated proteins (MMR), namely by somatic mutations in DNA 
mismatch repair protein Msh2 and 3 (MSH2 and 3) (Galluzzi et al., 2011; Kamal et 
al., 2010). MSH2, together with MSH3, forms the MutSβ heteroduplex that interacts 
with interstrand cross-links induced by drugs such as Cisplatin (Kamal et al., 2010; 
Kelland, 2007). A recent retrospective study has shown a border line association 
between the over-expression of several DNA repairing proteins, including MSH2, 
and chemoresistance in non-small-cell lung cancer patients (Kamal et al., 2010). 
Similarly, Fouret et al. has also demonstrated that the expression of MSH2 was 
associated with lower survival in non-small-cell lung cancer patients. Takahashi et 
al. (2011) has further demonstrated that MSH3 deficiency contributes to the 
cytotoxicity of platinum drugs through deficient double strand breaks repair in 
colorectal cancer cell line HCT116.  
Likewise, disruption of the homologous recombination (HR) system, 
responsible for repairing DNA double-strand breaks during de S phase of the cell 
cycle, have been shown to modulate response to Cisplatin (Galluzzi et al., 2011; 
Joshi et al., 2014; Rytelewski et al., 2014). In particular, breast cancer susceptibility 
gene 1 and 2 proteins (BRCA1/2) play an important role in DNA repair via 
transcription-coupled nucleotide excision and act as a checkpoint of cell cycle 
control, transcriptional regulation, and ubiquitination (Joshi et al., 2014; Rytelewski 
et al., 2014). Loss of function mutations in genes encoding HR system proteins 
BRCA1/2 were associated with decreased response to Cisplatin in breast and 
ovarian tumors (Joshi et al., 2014; Rytelewski et al., 2014). Namely, it has been 
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observed that carriers of BRCA1 mutations develop breast tumors that grow rapidly 
and are high grade and estrogen receptor negative (Foulkes, 2004; Tischkowitz and 
Foulkes, 2006). Also, decreased BRCA1 mRNA expression in breast and ovarian 
cancer cell lines have been found to enhance Cisplatin sensitivity, while the 
opposite phenomenon is observed in the presence of normal or high levels of 
BRCA1 (Kennedy et al., 2004). Furthermore, several retrospective clinical studies 
have demonstrated that low BRCA1 mRNA expression was associated with longer 
survival of breast, ovarian, bladder and small lung cell carcinoma (Font et al., 2011; 
Margeli et al., 2010; T. B. Wang et al., 2014) submitted to Cisplatin-based 
therapeutic regimens, and could be therefore used as predictive and prognostic 
markers. In addition, several studies, recently comprehensively reviewed by Buckley 
et al. (2013), suggest a role for BRCA1 in stem cell regulation through activation of 
the p63 and Notch pathways (Buckley et al., 2013). Altogether, these studies 
support that functional mutations of the BRCA1 gene, but also reduced expression 
levels, could predict a benefit from DNA-damage-based chemotherapy. 
Furthermore, it highlights a link between BRCA1, stem cell regulation and response 
to chemotherapy.  
More detailed information regarding the role of DNA repairing systems in 
resistance to platinum-based treatment can be found in recent reviews by Jin and 
Robertson (2013) and by Krejci et al. (2012). 
2.5. Changes in apoptosis regulatory pathways 
The cytotoxic effect of Cisplatin is primarily mediated by the activation of a 
multi-branched pro-apoptotic signaling cascade in response to the impossibility to 
repair DNA damage. Details on these mechanisms have been extensively and 
comprehensively reviewed by several authors (Igney and Krammer, 2002; Lowe and 
Lin, 2000; Schmitz et al., 2000). As such, response to Cisplatin dependence on 
functional apoptotic pathways and genetic and epigenetic alterations in genes 
encoding key mediators of this process has been long recognized to associate with 
drug resistance (Dasari and Bernard Tchounwou, 2014; Galluzzi et al., 2011; Shen 
et al., 2012).These events may either result in enhanced survival stimuli, diminished 
death stimuli or diminished sensibility to death signals. Perhaps the most well 
documented and widely expressed apoptosis-related deregulation associated with 
Cisplatin resistance stems from the inactivation of tumor suppressor protein TP53 
(Cavallo et al., 2013; Galluzzi et al., 2014; Vousden and Lane, 2007). Furthermore, 
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several studies demonstrate that cancer patients harboring wild-type p53 gene 
reportedly have a higher probability to benefit from Cisplatin-based chemotherapy 
than patients with p53 mutations (Chee et al., 2013; Gadducci et al., 2002; Liang et 
al., 2011). On the other hand, testicular germ cell tumors, which are known to be 
sensitive to Cisplatin, are among the few cancers in which TP53 is rarely inactivated 
(Peng et al., 1993), reinforcing the key role of p53 as a mediator or chemotherapy 
response. Other p53-related nuclear transcription factors, namely p63 and p73, are 
also part of a network  that together with p53 contributes to regulating both 
apoptosis and tumourigenesis (Flores et al., 2005, 2002) as well as the response to 
DNA damage induced by chemotherapeutics (Leong et al., 2007; Müller et al., 2006; 
Rocco et al., 2006; Yuan et al., 2010). Multiple promoters and alternative splicing 
events result in the expression of an array of isoforms for these transcripts, which 
include full length isoforms with transactivation domain (TA) homologous to that of 
full length p53, and amino-terminally truncated (DeltaN) isoforms, which lack the 
TA domains. The TA isoforms of p63 and p73 are able to active downstream target 
genes and promote apoptosis. Conversely, the DeltaN isoforms may act as 
dominant inhibitors of the full-length forms of p53, p63 and p73, impairing the 
activation of target genes and induction of apoptosis upon chemotherapy challenge. 
Several studies have further demonstrated that interfering with the expression or 
function of DeltaNp63 and/or DeltaNp73 and/or mutant p53 in tumor cells 
contributes to improve tumor response to chemotherapy (Leong et al., 2007; Müller 
et al., 2006). 
 Alterations in other protein responsible for mediating apoptosis triggered 
either by damage in the DNA or oxidative stress via the mitochondrial pathway or 
by the extrinsic route may also influence sensitivity to Cisplatin. Several death 
receptors, cytoplasmatic adaptors, pro- and anti-apoptotic members of the Bcl-2 
protein family, caspases, calpains, mitochondrial intermembrane proteins are 
among the proteins shown to modulate the response to Cisplatin in vitro (de La 
Motte Rouge et al., 2007; Janson et al., 2010; Sakai et al., 2008; Tajeddine et al., 
2008; Wang et al., 2010) and some have been suggested to modulate clinical 
response. Namely, elevated levels of pro-apoptotic BCL-2 family members and their 
anti-apoptotic counterparts BAX and BAK, BCL-2, BCL-XL and MCL-1 were found 
associated with Cisplatin resistance and tumor recurrence in different types of 
tumors (Erovic et al., 2005; Han et al., 2003; Michaud et al., 2009; Williams et al., 
2005). Studies involving the combination of Cisplatin with BCL-2-like inhibitor 
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proteins ABT-263 and ABT-737 have shown to improve the response to Cisplatin 
and other Platinum-based drugs. The mathematical model built by these 
investigators got to predict that co-plus post-treatment of ABT-
737 with Carboplatin may be the best strategy to maximize synergism between 
these two drugs (Jain and Meyer-Hermann, 2011). The over-expression of survivin,  
a caspase-inhibitory protein often upregulated in response to Cisplatin by 
phosphoinositide-3-kinase (PI3K)/AKT1-dependent mechanisms (Ikeguchi and 
Kaibara, 2001), has also been associated with lack of response to Cisplatin and 
unfavorable outcome in gastric (Nakamura et al., 2004), esophageal (Kato et al., 
2001) and NSCLC tumors (Karczmarek-Borowska et al., 2005). The administration of 
survivin inhibitors (for example, YM155, LY2181308)  have been also found to 
improve the outcome of several malignancies (Congmin et al., 2006; Ryan et al., 
2009).  
 Several of the above described mechanisms have been found to endow CSC 
with the capability to evade death signals and therefore constitute the Achilles heel 
of chemotherapeutic sensitization (Fulda, 2013; Signore et al., 2013). More detail 
insights on the mechanisms regulating the apoptosis pathways in CSC can be found 
in Medina et al., 2009. As recently revised by Signore et al. several strategies 
exploiting the apoptotic pathway to directly or indirectly kill CSC are currently 
approved or being tested in clinical settings (Signore et al., 2013). Strategies to 
sensitize CSC to chemotherapy include the stimulation of death receptors using 
Apo2L/TRAIL inducers (Plasilova et al., 2002; Ravi et al., 2004). By promoting the 
activation of the apoptotic extrinsic pathway, this strategy presents potential to 
overcome drug resistance in many tumors presenting with p53-inactivating 
mutations (Ashkenazi et al., 2008). Several antibodies and small molecules 
targeting the mitochondria-associated apoptosis machinery have also been 
developed, namely the Bcl-2 antagonizer ABT-727 that was able to sensitize glioma 
CSC to TRAIL treatment both in vitro and in vivo (Tagscherer et al., 2008). The 
inhibition of the EGF-R/Akt pro-survival signaling is also among the most explored 
strategies to induce indirect apoptosis of CSC (Gallia et al., 2009; Signore et al., 
2013). Despite the significant success presented by these strategies, it is now 
consensual that CSC subpopulations with distinct genetic and phenotypic features 
may co-exist within the same tumor (L. Li et al., 2012; Richard et al., 2013) and 
significant molecular variations were also observed between CSC isolated from 
tumors of the same and different organs . This heterogeneity accounts for 
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significant variations in response to targeted strategies and highlights the need for 
a careful evaluation of the signal transduction pathways that drive each 
subpopulation of CSC to evade apoptosis, towards personalized cancer treatments. 
Furthermore, despite the encouraging reports about patient-derived xenografts 
capable of recapitulating CSC expression and tumor heterogeneity in immune 
deficient animals (Richard et al., 2013; van der Horst et al., 2012; Zhou et al., 
2014), more efforts should be devoted to the development of reliable clinical 
models able to support the development of new anti-cancer technologies.  
  
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein glycosylation as a regulator of 
chemotherapy response  
  
24 
 
3. Protein glycosylation as a modulator of chemotherapy response 
Glycosylation is the most frequent, complex and plastic posttranslational 
modification of membrane-bound and secreted proteins and results from a 
coordinated action of nucleotide sugar transporters and biosynthesis pathways and 
glycosyltransferases and glycosidases in the endoplasmatic reticulum (ER) and the 
Golgi apparatus (GA)( Pal K et al, 2011). Glycans play a key role in protein folding, 
trafficking and stability and act as mediators of cell-cell adhesion, cell 
differentiation, migration, cell signaling pathways, immune recognition and host-
pathogen interactions. Two main classes of glycans can be found at the cell-surface: 
i) O-glycans, initiated in the ER by the initial attachment of GalNAc residues to the 
hydroxyl groups of a Serine (Ser) or Threonine (Thr) (the Tn antigen; GalNAcα-
Ser/Thr) of a given polypeptide chain (forming the Tn antigen, the simplest form of 
O-glycosylation); ii) N-glycans, whose biosynthesis initiates in the GA by the addition 
of an oligosaccharide chain to an Asparagine residue (Asn) within a consensus 
peptide sequences of Asn-X-Ser/Thr (X denotes any amino acid except proline). Less 
abundant forms of protein glycosylation include O-Fucosylation, O-Glucosylaton and 
C-mannosylation of Thr residues. These glycan chains are often branched or 
elongated and may present sialic acids, Le blood group related antigens or ABO(H) 
blood group determinants as terminal structures. Other modifications may include 
phosphorylation, O-acetylation of sialic acid and O-sulfation of galactose and N-
acetylglucosamine residues, thereby increasing the structural complexity of the 
glycophenotype. Intracellular proteins may also present O-linked β-N-
acetylglucosamine (O-GlcNAc) residues as posttranslational modifications. This is a 
highly dynamic, regulatory and reversible modification governed by O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA) in response to UDP-GlcNAc levels in the 
hexosamine biosynthetic pathway (HBP). O-GlcNAcylation varies with glucose fluxes 
and competes with phosphorylation for serine and threonine residues.  This 
modification integrates metabolic signals that act to influence many cellular 
processes, including cellular signaling, protein stability, and transcription. Protein 
glycosylation patterns do not obey a predefined template, as it is regulated at the 
tissue level, and promptly responds to physiological changes (Shental-Bechor D and 
Levy Y, 2009). In fact, variations in glucose and oxygen levels, among other 
microenvironmental factors, have been shown to influence the transcription and 
activity of glycosyltransferases and glycosidases, the trafficking of these enzymes 
to the ER and GA and the availability of sugar donors. This makes of 
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glycomic/glycoproteomic characterization a challenging analytical enterprise that 
mirrors a particular biological milieu. Detailed insights on the structure of these 
glycans and their biosynthesis are available in several recent reviews on the subject 
and will not, therefore, be discussed in detail (Dall’Olio F et al, 2012). 
 
Figure 1 – Aberrant glycosylation forms (Julien S, 2012).  
Malignant transformations are often accompanied by the expression of 
glycosylated structures that promote tumor growth, inhibit cell-death, favor cell-to-
cell detachment, migration, immune evasion and metastization. In some cases 
malignant tissues recapitulate the glycosylated antigens expressed during fetal life 
(Dall’Olio F et al, 2012). Perhaps the most studied cancer-associated glycan includes 
variants resulting from a premature stop in the O-glycosylation of proteins (see 
Figure 1), namely the Tn antigen (the simplest O-glycan), its sialylated counterpart 
sialyl-Tn (sTn; Neu5Ac2-6GalNAc-O-Ser/Thr) and the T or core 1 antigen that 
results from the addition of a Gal residue to the Tn antigen (Galβ1-3GalNAc-
Ser/Thr). These antigens have been classically termed simple mucin-type O-glycans 
reflecting the abundance of O-glycosylation sites in mucins and stem from the 
incapability of the cell glycosylation machinery to produce more elongated glycans 
(Clement M. et al, 2004). Recently, a precision mapping of human O-GalNAc 
glycoproteome has revealed over 6000 glycosites in more than 600 O-
glycoproteins, the majority of which were to be found at the cell surface, thereby 
greatly expanding the view of the O-glycoproteome and its functional role. Of note, 
several intracellular proteins, including cytoplasmatic, mitochondrial and nuclear 
proteins, have also been found expressing this type of posttranslational 
modification. Despite the need for further analytical validation, these observations 
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may suggest an up until now neglected role for O-GalNAc glycosylation in 
intracellular events. While hindered by extended glycosylation in healthy and benign 
tissues, simple type O-GalNAc glycans are uncovered in the majority of human 
carcinomas, particularly in advanced stages of the disease. Both the Tn, sTn and T 
antigens have been associated with malignant cell phenotypes and disease 
progression, metastasis and poor prognosis in clinical settings for a variety of 
different solid tumors, in particular of gastrointestinal nature but also breast, lung 
and ovarian cancers.  Recently, Ferreira et al. (2014) observed that sTn was also 
associated with high-grade bladder cancer and muscle-invasion as well as with the 
capability of bladder cancer cells to impair dendritic cells recognition, thereby 
promoting a tolerogenic immune response (Santos J., et al, 2014; Ferreira et al., 
2013). The fact that these simple glycans are absent, significantly under-expressed 
or restricted to some cell types in healthy tissues, makes them ideal diagnostic and 
therapeutic targets. Proteins carrying these glycans are often released from the cell-
surface and contribute to elevated sTn concentrations in serum (CA72-4 test) in 
gastric, colorectal and pancreatic carcinoma patients as well as in gastric pre-
cancerous lesions. The elevation of CA72-4 is considered to be useful as an 
independent prognostic factor in gastric cancer and tumor recurrence in gastric and 
pancreatic cancers. Also, several monoclonal antibodies have been developed for 
sTn as well as the therapeutic vaccine Theratope that, despite promising upfront 
results in pre-clinical and early stage clinical trials for advanced breast tumors, 
remains to be comprehensively accessed in clinical settings in other tumors (Santos 
J., et al, 2014).  
Several evidences also point to an increase in complexity of N-linked glycans 
and also glycolipids by 1,6 branching, mediated by β1,6-N-
acetylglucosaminyltransferase V (Mgat5) in cancer. The β-1,6-N-acetylglucosamine 
branched glycans are responsible by the  high-affinity binding of Galectin-3 to many 
glycoproteins and glycolipids in the cell membrane, including carcinoembryonic 
antigen (CEA), mucin-1, lysosomal membrane associated glycoproteins (LAMPs)-
1and -2 , Mac-1 and Mac-3, CD-98, CD-45, CD-7, and the glycosylated 
transmembrane tyrosine kinase receptors for epidermal growth factor (EGF), 
transforming growth factor beta (TGF-b), vascular endothelial growth factor (VEGF), 
among other relevant cancer-associated proteins (Julien S et al, 2005). Galectin-3 
promotes multimeric lattices with cell surface glycoprotein receptors originating 
functional microdomains responsible by ensuring proper transmission of 
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extracellular signals to the cells as well as glycoprotein receptor turnover and 
endocytosis. As recently highlighted by Fortuna-Costa et al. galectin-3 mediates 
several hallmarks of cancer, including tumor growth, anoikis resistance, apoptosis 
inhibition, angiogenesis, cell adhesion, cell motility, and cell invasion as well as 
microenvironment modulation. Increased β1,6 branching of cadherins, integrins and 
other cytokine/growth factor receptors have also been found to enhance and 
promote tumor growth and metastasis while the Mgat5 knockout inhibited these 
phenomena in vitro and in vivo in different cancer models.  
Two other common cancer-associated antigens are the 2,3 sialylated forms of 
type 1 and type 2 Lewis blood group determinants Le
a
 and Le
x
, sLe
a
 and sLe
x
. These 
glycans are specific ligands for E- and P-selectin in endothelial cells, two proteins 
that mediate leukocyte extravasation at sites of tissue injury in a sLe
a
/sLe
x
-
dependent way (Pal K et al, 2011). Similarly, the expression of these sialylated 
glycans by tumor cells is thought to act as a regulator of the metastatic cascade, 
promoting cell adhesion to the endothelial wall and consequently promoting cell 
intravasation to distant organs. In addition to a role in metastasis, selectin ligands 
are also thought play a role in tumor growth and angiogenesis. In particular, several 
reports associate the over-expression of sLe
a
 with decreased overall survival in 
gastric, colon and pancreatic cancer, among others. Furthermore, serological 
detection of sLe
a
 on glycolipids and glycoproteins by the CA19-9 assay is used to 
monitor clinical response to therapy in pancreatic, colorectal, gastric and biliary 
cancer and as a prognostication tool in patients diagnosed with colon and gastric 
cancer (Pal K et al, 2011).  
The 2,6-oversialylation of lactosamine chains and over-fucosylation of terminal 
motifs are also among some of the commonly observed structural changes in 
cancer cells. An association between α2,6-sialylation and invasive growth has been 
suggested by several studies and the over-sialylation of  1 integrin has been found 
to modulate intracellular signaling pathways towards increased cell survival. 
Different mechanism may account for the above described structural features, 
which may include alterations in transcription of biosynthetic and degrading 
enzymes, derangement of secreting organelles and availability of sugar nucleotides, 
promoted either by micro environmental pressure and/or dysfunctional glycogenes. 
Altogether, abnormal glycosylation is considered a typical hallmark of the transition 
from healthy to neoplastic tissues with direct influence in the modulation of cell-
behavior. Since these alterations take place at the cell-surface originating highly 
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distinct protein glycovariants, it presents an opportunity for targeted therapeutics 
(Dall’Olio F et al, 2012). However, as highlighted by recent publications, both 
similarities and differences exist in the glycosylation patterns in different tumors, 
mirroring the dynamic nature of the glycome. Furthermore, the same glycans may 
present opposite biological roles in different tumors, denoting the need for a 
comprehensive analysis of the glycoproteome in the clinical context, towards 
personalized cancer treatment. 
 Several studies have described that subpopulations of multidrug resistant 
cancer cell lines of different origins present altered glycosylation patterns, 
particularly at the N-glycosylation level, when compared with the parental cell lines. 
Alterations in glycogenes expressions were also reported and, in most cases, have 
been found to be in agreement with the observed glycosylation patterns. In 
addition, some studies have further associated the over-expression of cell-surface 
ATP binding cassette transporters (MRP1, MRP5) and CD147 showing defective N-
glycosylation patterns with drug resistance. In an attempt to establish a cause-effect 
relationship between these events, MRP cells’ response to chemotherapy was also 
evaluated after exposure of the cells to tunicamycin, a blocker of the N-glycans 
biosynthesis. This impaired N-glycosylation without significantly compromising the 
expression of these proteins, and also enhanced the sensitivity to chemotherapy. 
All thought these observations strongly suggest that alterations in N-glycosylation 
may alter the functional properties of cell-surface proteins involved in drug 
resistance, it should be noticed that the used compound is responsible for inducing 
significant ER stress. Namely, N-glycosylation shutdown may lead to the formation 
of non-functional proteins thereby modulating the response to treatment by protein 
inhibition. Altogether, the notion prevails that glycosylation might constitute an, up 
until now, neglected molecular alteration in resistance to chemotherapy. 
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4. Aims and Scopes 
Standard treatment for stage T3, T4 and stage T2 with ganglia metastasis 
Bladder Cancer are Cisplatin-based regimens, frequently used as neo and adjuvant 
treatment for solid tumors (Gakis et al., 2013). This drug in combination with 
others has proven to be highly effective against proliferative cells that constitute the 
tumour bulk. However, relapse rates are as high as 95% and 5-year survival rates as 
low as 15-20%, which represents a heavy burden for both health care systems and 
patients (Nadal and Bellmunt, 2014). Currently these relapse rates and low survival 
of patients is thought to be due to several molecular mechanisms that induce drug-
resistance. Recent works showed that some subpopulations of chemoresistant cells 
share properties associated with CSC, known to migrate and invade other tissues. 
Furthermore, aberrant glycosylation is a recognized hallmark of cancer and recent 
published works indicate that over-expression of the STn is associated with low 
proliferating muscular invasive bladder tumors (Bernardo et al., 2014; Ferreira et 
al., 2013; Videira et al., 2009). Being present only in malignant bladder cells and in 
low-proliferating areas of the tumor, STn is thought to be a promising determinant 
of those 10 to 20% of urothelial cell carcinomas that evolve towards invasion of the 
muscularis propria.  
Aiming to understand if STn have a prognostic value both for treatment 
outcome and patient OS and if it is a suitable marker for bladder cells resistant to 
Cisplatin treatment. Therefore the specific aims of this thesis are: 1) to determine 
and compare STn, p53 and Ki-67 immunoreactivity in NMIBC and MIBC; 2) to 
establish, if possible, a relation between STn positivity and p53 and Ki-67 
immunoreactivity; 3) to understand STn immunopositivity distribution within 
bladder cancer pathology and, more specifically, within MIBC; 4) to explore the 
possibility that STn is linked to more progressed and aggressive bladder tumors, as 
suggested by the literature, and evaluate its value as a predictive, prognostic and 
targeting biomarker; and 5) to validate, through an in vitro assay, that STn is 
present in Cisplatin resistant cells and appreciate their stem-like characteristics. 
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5. Material and Methods 
5.1. Patients 
This study was performed in a retrospective series of 120 cases of muscle-
invasive bladder cancer. Patients underwent consultation, surgery and adjuvant 
chemotherapy in the Portuguese Oncology Institute of Porto, between 2002 and 
2013. The male/female ratio was of 9:1 and the mean age was 68,6 years-old. 
Tumour staging was obtained from patients' clinical records and further reviewed 
by a pathologist according to the current TNM (tumour, node, metastasis) 
classification (see Table 1) and, for further analysis T3 and T4 staged tumours were 
evaluated together and compared against T2 staged cases. Additionally, 23 
metastases were also evaluated, from which 8 had correspondent primary tumours. 
Also, in order to better evaluate the relevance of the sample analysed, 47 cases of 
non muscle-invasive bladder cancer (NMIBC) were added to the total sample as a 
comparison group. All procedures were performed after patient’s informed consent 
and approved by the Ethics Committee of IPO-Porto. All clinicopathological 
information was obtained from patients’ clinical records. All tumor samples were 
revised by a pathologist, regarding 2004 WHO grading criteria and TNM 
classification (2010). 
Table 1 - Clinicopathological characterization studied cases.  
Clinicophatological Characteristics 
  Count (%) 
Gender M 108 (90,0) 
F 12 (10,0) 
Pathology NMIBC
a
 
47 (-) 
MIBC
b
 
120 (-) 
Metastasis 23 (-) 
Stage T2 24 (20,0) 
T3 54 (45,0) 
T4 34 (28,3) 
Ganglionar 
metastasis 
Absent 68 (56,7) 
Present 37 (30,8) 
Metastasis Not found or absent 112 (-) 
Present 8 (-) 
a
NMIBC - non muscle-invasive bladder cancer; 
b
MIBC - 
muscle-invasive bladder cancer 
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5.2. STn, p53 and Ki-67 expression in bladder tumors 
Formalin-fixed paraffin embedded tissue sections were screened for STn, p53 
and Ki-67 by immunohistochemistry using the avidin/biotin peroxidase method, as 
described by Ferreira et al. (2013). STn expression was evaluated with anti-STn 
mouse monoclonal antibody clone TKH2 (Ferreira et al., 2013) which was provided 
from Professor Celso Reis (IPATIMUP); wild-type (wt) and mutant-p53 proteins were 
labelled with monoclonal mouse anti-human p53 protein, clone DO-7 (Dako, 
Barcelona); and Ki-67 expression was determined using monoclonal mouse anti-
human Ki-67 antigen, clone MIB-1 (Dako, Barcelona). All antigens were assessed by 
two independent observers. Upon disagreement, slides were reviewed until a 
consensus was reached.  
Tumours were classified as negative when immunoreactivity of anti-STn TKH2 
antibody was present in 20 cells or less of total tissue, low-positive when present in 
more than 20 cells and under 20% of total tissue, positive when immunoreactivity 
ranged from 20 to 50% and highly-positive when immunoreactivity surpassed 50% 
of total tissue (Ferreira et al., 2013). For further analysis, STn immunoreactivity was 
divided in two groups: 1- non-expressing tumours, including those considered 
negative and low-positive; and 2- expressing tumours, including those considered 
positive and highly-positive.  Tumours tested for wt- and mutant-p53 proteins were 
classified as positive when immunoreactivity was observed in over 20% of total 
tissue and negative when less than 20% of total tissue presented with 
immunoreactivity. Concerning Ki-67, tumours were considered non-proliferative for 
immunoreactivity under 17% of total tissue, proliferative for values between 17 and 
49% and highly-proliferative for values over 50%. For further analysis Ki-67 
immunoreactivity was divided in two groups: 1- non-proliferative tumours, 
comprising tumours with 17% or less immunoreactivity within the entire tissue 
section; and 2- proliferative, including tumours with immunoreactivity in more than 
20% of the tissue section. 
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5.3. T24 bladder cells culture 
The cell line used in this work was T24 which was provided from Professor 
Rosário Pinto-Leite of the Vila Real Hospital, and are derived from a transitional cell 
carcinoma of an 81 years-old Caucasian individual. Cells were previously 
characterized in order to access cross-contamination.  According to Pinto-Leite et al. 
(2014) T24 presents an invasive phenotype characterized by an active 
FGFR3/CCND1 pathway, presenting mutated HRAS and over-expressed CCND1 by 
the gain of 11q13 band in the 11p15.1q14 gain (Lindgren et al., 2012; Pinto-Leite 
et al., 2014). Cells were cultured and processed as exposed in Figure 2. 
 
Figure 2 – Experimental design for T24 cells analysis. Cells were cultured in RPMI 1640 with 
GlutaMAX (TM), HEPES medium (Gibco), supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco) and 100 μg/mL penicillin/streptomycin (Gibco). Cells were cultured as monolayer at 37oC in 5% 
CO
2
 in a humidified atmosphere. Cells were allowed to recover from cryopreservation for a 72hour 
period and were divided in two groups. The first (non-exposed) was maintained without exposure to 
Cisplatin, and cells were routinely subcultured by trypsinization; the second group was exposed to 
Cisplatin in a IC50 concentration of 2,5 mg/mL for a 72hour period (Pinto-Leite et al., 2014) and 
allowed to recover for a 30 day period. Subsequently both patches were SNAP-frozen and then kept at -
80
o
C while awaiting further analysis. 
5.4. RNA extraction and conversion and real-time PCR 
Total RNA was extracted and purified from frozen samples of cultured T24 
bladder cancer cells using PureLink RNA Mini Kit (Ambion, Life technologies). RNA 
quantity and quality were accessed using a Nanodrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc). 
Total RNA was converted to cDNA through reverse transcriptase reaction using 
a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA, USA). Reverse transcriptase reaction contained a total volume of 60μL reaction 
mix with: 30μL of master mix containing 1x RT Buffer, 6.25mM of total dNTPs, 
150U MultiScribe Reverse Transcriptase Enzyme (Applied Biosystems, Foster City, 
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CA, USA) and 6μg of RNA. The amplification conditions were the following: 
annealing at 25ºC for 10 minutes (min.), extension at 37 ºC for 120 min. and RT 
inactivation at 85ºC for 5 min. All reverse transcriptase reactions included two no-
template controls (as negative controls double distilled water replacing template 
RNA was used). 
The transcript levels of a 21 genes panel and 2 housekeeping genes were 
quantified by quantitative polymerase chain reaction (qPCR) on an StepOnePlus™ 
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with a 10μL final 
volume mixture containing 1x TaqMan
®
 Universal PCR Master Mix II (Applied 
Biosystems, Foster City, CA, USA), TaqMan
®
 Gene Expression Assays (Thermo Fisher 
Scientific) (see Table 2) and 1μL cDNA (reverse transcriptase product). Thermal 
cycling conditions were: 10 min. at 95°C followed by 45 cycles of 15 seconds (sec.) 
at 95°C and 1 min. at 60°C.  All reactions were run in duplicate.   
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Table 2 - TaqMan Gene Expression Assays references used to assess transcript 
levels for the 23 determined genes.  
TaqMan Gene Expression Assays references 
Cell function Gene TaqMan Gene Expression Assay 
reference 
Self-renewal and stemness NANOG Hs04260366_g1 
LIN28A Hs01552405_g1 
OCT-4 (POU5F1) Hs04260367_g1 
KLF9 Hs00230918_m1 
KLF4 Hs00358837_g1 
SOX2 Hs01053049_s1 
Epithelial phenotype CDH1 (E-cadherin) Hs01023894_m1 
DSP (Desmoplakin) Hs00950591_m1 
EpCAM Hs00901885_m1 
Mesenchymal phenotype FN1 (Fibronectin 1) Hs00365052_m1 
CDH2 (N-cadherin) Hs00983056_m1 
VIM (Vimentin) Hs00185584_m1 
Extracellular matrix synthesis and 
promotion of changes to cell shape 
SPARC 
Hs00234160_m1 
EMT SNAI1 Hs00195591_m1 
SNAI2 Hs00950344_m1 
TWIST1 Hs01675818_s1 
TWIST2 Hs00382379_m1 
ZEB1 Hs01566410_m1 
ZEB2 Hs00207691_m1 
RUNX1 Hs01021971_m1 
RUNX2 Hs01047973_m1 
Reference genes
1
 GAPDH Hs03929097_g1 
ActB 
Hs99999903_m1 
1
Reference genes were accessed for stability. Only ActB was used for increase fold calculi, because GAPDH was not 
stable enough. 
5.5. Protein extraction and Slot-blot 
Proteins were extracted from frozen T24 bladder cancer cells sample on RIPA 
buffer (with 10μg/mL protein inhibitors) and the amount of protein in each extract 
was estimated with RC protein assay kit (BioRad). The quantity of the extracted 
protein ranged from 156,5 to 369,1µg. Twenty-five micrograms of protein were 
slot-blotted onto 0.45 m nitrocellulose membranes (GE Healthcare). Membranes 
were blocked with  1% carbohydrate depleted carbo-free solution (Vector 
laboratories) for 1 h at room temperature, incubated overnight at 4ºC with anti-sTn 
TKH2 monoclonal antibody in culture supernatant, washed with TBS-T for 30 min, 
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and finally incubated for 45 h with goat anti-mouse IgG1 heavy chain horseradish 
peroxidase conjugate (Abcam; 1:90,000 in TBS). After washing, the bound 
antibodies were revealed by chemiluminescence using the ECL prime Kit (BIORAD). 
Samples previously de-sialylated as previously described by Marcos et al. (Marcos et 
al., 2011) were used as controls. 
5.6. Data analysis 
Statistical analysis was performed using the IBM Statistical Package for Social 
Sciences for Windows (version 20.0). Chi-square analysis was used to compare 
categorical variables. Correlation between STn, p53 and Ki-67 immunoreactivity and 
clinical variables was performed using Pearson test. Kaplan-Meier survival curves 
were used to correlate the different types of BC, STn and p53 and Ki-67 
immunoreactivity with the OS of patients with BC; log rank statistical test was used 
for curves comparison. 
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6. Results presentation and discussion 
6.1. Classical bladder cancer markers (p53 and Ki-67) expression  
p53 and Ki-67 are well described antigens in bladder cancer molecular 
characterization studies (Sanguedolce et al., 2014). Since the late 1980s p53 has 
been pointed as a key molecule in carcinogenesis and disease progression 
(Sanguedolce et al., 2014) and, in bladder cancer, its over-expression constitutes an 
early alteration in BC carcinoma in situ (CIS) cases (Sarkis et al., 1994). Studies have 
been conducted in order to understand the relevance of p53 as a predictor of 
disease progression and disease-free survival (Sanguedolce et al., 2014). Most 
studies that evaluate p53 expression through immunohistochemistry (IHC) and 
qPCR, indicate p53 as being associated with poor-prognosis and poor patient 
outcome, being present in more advanced and aggressive tumors and being a 
useful biomarker for therapy selection (Garcia del Muro et al., 2004; Goebell et al., 
n.d.; Kuczyk et al., 1995; Lopez-Beltran et al., 2004; Popov et al., 1997; Sarkis et al., 
1995, 1994; Shariat et al., 2010). However, there are some contradictory findings, 
some studies  indicates a tenuous or no relation between p53 over-expression and 
patient outcome and disease progression (Dalbagni et al., 2007; Thomas et al., 
1994; Tzai et al., 2004).  
p53 relevance has also been studied for NMIBC and results suggest its value as 
a predictive biomarker (Ecke et al., 2008; Llopis et al., 2000; Rodríguez-Alonso et 
al., 2002). Ecke et al. (2008) analyzed p53 mutation in NMIB tumors, and concluded 
that the presence of mutant-p53 in NMIB tumors is a predictive factor of poor 
outcome and disease progression (Ecke et al., 2008). Conversely, Dalbagni et al. 
(2007) found no difference in disease-specific survival (DSS) between patients with 
and without over-expression of p53, for first diagnosed T1 transitional cell 
carcinomas (TCC).  
Ki-67 nuclear antigen is a surrogate biomarker of cellular proliferation and is 
commonly assed by IHC using the MIB1 antibody (Sanguedolce et al., 2014). It is 
associated with poor patient outcome when mutated or over-expressed (van Rhijn et 
al., 2010), disease progression and aggressiveness (Margulis et al., 2009, 2006; 
Stavropoulos et al., 1993; van Rhijn et al., 2003) and decreased OS, in patients with 
MIBC (Lopez-Beltran et al., 2004); and with tumor recurrence, stage progression and 
decreased DFS and OS in patients with NMIBC (Gontero et al., 2000; Pich et al., 
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2002; Quintero et al., 2006; Ramos et al., 2004; Santos et al., 2003). However, 
some studies failed to prove Ki-67 utility as a tool in disease and outcome 
evaluation (Behnsawy et al., 2011; Lebret et al., 2000; Pfister et al., 1999). In this 
work, both antigens were assessed by IHC, aiming to understand their distribution 
and possible influence in this series of cases. 
Table 3 - Relation between Ki-67 and p53 immunoreactivity and tumor grade and 
presence of ganglionar metastasis 
Ki-67 and p53 labelling within MIBC and ganglionar metastasis 
 
T2 vs T3T4 p 
value
a
 
Ganglionar 
metastasis 
p 
value
a
 
 T2 T3/T4 Absent Present 
Ki-67 negative (%) 77,30 87,30 
0,213 
84,20 85,70 
0,807 
Ki-67 positive (%) 22,70 12,70 15,80 14,30 
p53 negative (%)
b
 22,70 22,20 
0,961 
26,30 14,30 
0,211 
p53 positive (%)
b
 77,30 77,80 73,70 85,70 
 a
 Pearson Chi-square test; 
b
 anti-p53 DO-7 antigen binds to both wt- and mutated-p53. 
 
Contrary to the information found in literature, from the 85 MIB tumors 
evaluated for Ki-67 presence, 84,7% were considered non-proliferative (expression 
was present in less than 17% of tissue sections) and 15,3% were labeled as 
proliferative. OS was assessed by comparing Ki-67 positive and negative cases 
within the MIBC group but no differences were observed in patients OS between the 
two groups (p=0,297, see Figure 4). Ganglionar metastasis was also evaluated and 
no significant difference was found in Ki-67 expression (see Table 3, p=0,807). 
Conversely, 87,3% of stage ≥T3 tumors were Ki-67 negative, compared with 77,3% 
of stage ≤T2, suggesting a slight tendency (despite not statically significant, 
p=0,213) for decreased cellular proliferation in more aggressive tumors.  
In this case, Ki-67 seems to relate only with tumor progression and probably 
with patients OS. Nevertheless, the number of cases analyzed needs to be increased 
in order to better understand if the relation between this antigen’s presence and 
tumor staging and patients OS is real. Possibly, non- our less-proliferative tumors 
are able to evade Cisplatin cytotoxicity, due to decreased mitotic and DNA 
duplication rates, and to further invade and migrate.  
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Expecting to understand if Ki-67 and STn presence are related in these tumors, 
immunopositivity and distribution of both were compared. No relation was found 
between their presence (p=0,733), however STn expression prevails in Ki-67 
negative areas which were assessed in consecutive sections of MIB tumors (see 
Figure 3). T3 and T4 tumors tend to form metastasis and to invade adjacent organs 
which is related with poor patient OS and treatment outcome. As described in the 
literature, non-proliferative tumors are able to adapt to the microenvironment and 
to minimize immune recognition and pharmacological impact. Therefore, STn 
presence (which is present in more aggressive tumors) in non-proliferative areas of 
those tumors (Ferreira et al., 2013) might indicate that it is a suitable marker for 
cells that do not respond to Cisplatin due to low mitotic rates and may be 
responsible for treatment resistance and tumor recurrence (see Figure 3).  
 
Figure 3 - Comparative expression of STn and Ki-67 (A and B) and expression of p53 
antigens (C). STn and Ki-67 expression do not correspond in sequential sections of the same tumor. 
The invasive carcinoma presented in these pictures (black arrow) and the dysplasic areas of the tumor 
(blue arrows) do not coincide for STn and Ki-67 presence. p53 expression is mainly present in tumor 
cells while less prevailing in normal cells.  
Regarding p53 immunoreactivity showed no differences were found when 
stage T2 and stage ≥T3 tumors were compared (p=0,961, see Table 3). Moreover, a 
higher expression of p53 was found in patients presenting ganglionar metastasis, 
yet no only a small tendency was found (p=0,211, see Table 3). Increased presence 
of p53 in tumors that tend to invade and migrate is was already been reported 
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(Sanguedolce et al., 2014) and seems to relate with poor patient OS and treatment 
outcome. However, in these samples no differences were found between patients 
OS and p53 presence (p=0,955, see Figure 4). Nevertheless, p53 immunopositivity 
appeared equally distributed throughout malignant cells and presented a lower 
expression in apparently normal cells. Since anti-p53 antigen labels both wt- and 
mutated-p53 proteins and that p53 mutations are described to be associated with 
poor patients OS and resistance to Cisplatin it seems relevant to further investigate 
if p53 is mutated in these cells through DNA sequencing.  
 
Figure 4 - Association between Ki-67 (A) and p53 (B) expression and patient OS. Kaplan-
Meier analysis and log rank test were used to assess the influence of Ki-67 and p53 in patients OS 
(p=0,2987 and 0,955, respectively). Ki-67+, Ki-67 positive cases; Ki-67-, Ki-67 negative cases; p53+, 
p53 positive cases; p53-, p53 negative cases. 
 
6.2. Expression of STn in bladder cancer and association with 
clinicopathological features 
Approximately 70% of the diagnosed bladder cancer cases (Z. L. Smith et al., 
2013) are non muscle-invasive (Ta and T1 staged tumors). However, of those, 50 to 
70% will recur and a significant percentage will progress to muscle invasive (≥T2 
staged tumors). Regardless of disease origin it is known that MIB tumors are more 
aggressive and yield a lower OS when compared with NMIB tumors (Breau et al., 
2014; Sanguedolce et al., 2014). In order to assess the representativeness of the 
used sample, the OS was revised by comparing patient outcome accordingly to the 
diagnosed pathology (MIBC vs. NMIBC). As expected, MIBC diagnosed patients 
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presented with decreased OS (44,1 months, p<0,001) when compared with NMIBC 
diagnosed patients (121,6 months), corroborating the MIBC aggressive 
development.  
 
Figure 5 - Association between disease nature and OS in the studied patients. Kaplan-Meier 
analysis was used to assess the relation between the presence of primary NMIBC or MIBC in patient OS 
and log rank test was performed (p<0,001). NMIBC, non muscle-invasive bladder cancer; MIBC, muscle 
invasive bladder cancer. 
Literature concerning sialyl-Tn presence in bladder cancer cells' surface is 
reduced. However, two recent studies conducted by Ferreira et al. (2013) and 
Bernardo et al. (2014) described that STn was present in approximately 70% of MIBC 
and is absent in normal urothelium. To evaluate the impact of STn in a wider 
context of bladder cancer pathology and aiming to determine if this molecule may 
have a predictive value or may be a relevant target for therapy, its expression was 
assessed both in MIBC and NMIBC, as shown in Table 4. STn was considered 
positive in 61,6% of total evaluated tumor sections and, from those, 69,6% were 
MIBC, corroborating that STn is most frequently present in more aggressive tumors, 
as indicated by Ferreira et al. (2013). Moreover, patients OS was found decreased 
for STn positive cases (67,8 months vs. 99,4 months for STn negative tumors; log 
rank p=0,022, Figure 6-A) demonstrating that more aggressive tumors express this 
molecule and raising the question about its behavior and impact within different 
stages of muscle-invasive tumors. 
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Table 4 - Relation between STn expression and disease nature and STn expression 
and patient outcome (OS) 
STn expression in NMIBC and MIBC 
 
NMIBC MIBC 
p 
value
a
 
 
Count (%) 
 
STn negative 27 (57,4) 34 (30,4) 
0,001 
STn positive 20 (41,6) 78 (69,6) 
   a
 Pearson Chi-square test. 
When only MIB tumours were taken into account no differences were found 
regarding OS between STn positive and negative tumours (p= 0,891, see Figure 6-B). 
Stage T2 tumours presented with a slight difference of the mean survival period: 
63,6 months for patients with STn positive tumours and 35,2 months for STn 
negative tumours (p=0,213). These results suggest a minor tendency for better OS 
in patients that present with stage T2 tumours with STn positivity. Since STn is most 
frequently found in non-proliferative areas of the tumour, a plausible hypothesis is 
that, for T2 tumours, which present lower proliferative rates are indicative of a 
lesser aggressive behaviour and/or of lower disposition for progression. However, 
further investigation of this subject is needed. 
Despite the apparent absence of prognostic value, 69,6% of the STn positive 
cases were MIBCs, suggesting that this antigen may play a preponderant role in the 
development of this disease and may have, as suggested by Ferreira et al. (2013), a 
significant impact on aggressiveness of muscle invasive tumours.  
Analysis of the STn presence within the MIB tumors indicated a higher 
positivity for more advanced stages of the disease (73,5% vs. 47,6% for stage ≥T3 
and T2 tumors, respectively, p=0,024, see Table 5). When STn distribution within 
the tumor cells (see Figure 7-B) was taken into account its presence in the invasive 
front of the tumor was higher in stage T2 cases (p=0,085). These results seem to 
contrast with the ones found for patient OS in STn positive stage T2 cases; however, 
no significant influence on patient OS was found (p=0,335; data not shown). 
Nevertheless, the overall results for STn within MIBC tumors suggest that it is 
present in more advanced stages of disease constituting a fairly good biomarker for 
disease progression. 
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(A)  (B)  
 
Figure 6 - Association between STn immunoreactivity within Bladder Cancer and patient OS 
(A) and association between STn immunoreactivity within MIBC and patient OS (B). Kaplan-Meier 
analysis was used to assess the relation between STn labeling and OS in patients with bladder cancer 
and the relation between STn immunoreactivity in patients with stage T3 and T4 tumors and their OS. 
STn -, STn negative cases; STn +, STn positive cases. 
To further understand if the previous results might in fact constitute a good 
starter for future investigations about STn, ganglionar metastases were taken in 
account. STn was present in 75% of the cases with ganglionar metastases opposing 
to 62,5% in the cases with no ganglionar involvement (p=0,185, see Table 5). Also, 
of those STn positive tumor presenting ganglionar metastases, 61,9% had 
preferential distribution of the antigen within the invasive front (p=0,050, see Table 
5 an Figure 7).  
 
 
Figure 7 - Expression of STn in bladder tumors. (B) - Primary tumor with STn labeling within 
the urothelial layers; (C) - Ganglionar metastasis with preferential allocation of STn labeling within the 
invasive front. 
A B
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Table 5 - Frequencies and relations of/between STn expression and the different tumor 
stages and the presence of ganglionar metastases and frequencies and relations of/between STn 
distribution within positive staining T2 and T3+T4 tumors and within positive staining 
ganglionar metastases. 
STn expression within the different tumour stages and within the 
ganglionar metastases 
 Tumour stage Ganglionar metastases 
 
T2 T3/T4 
p 
value
a
 
Absent Present 
p 
value
a
 
 Count (%) 
 
Count (%) 
 
STn negative 11 (52,4) 22 (26,5) 
0,024 
21 (37,5) 7 (25,0) 
O,185 
STn positive 
10 (47,6) 61 (73,5) 35 (62,5) 21 (75,0) 
 
STn within other 
localizations 
3 (30,0) 27 (60,0) 
0,085 
22 (64,7) 8 (38,1) 
0,050 
STn within 
invasion front 
7 (70,0) 18 (40,0) 12 (35,3) 13 (61,9) 
a
 Pearson Chi-square test. 
 
Therefore, STn may constitute a valuable aid in directing therapy for BC since 
it is present in almost 70% of MIBC cases wherein studied and most frequently in 
stage T3 and T4 tumours. Furthermore, for the first time, it is reported that STn 
presence in the primary tumour may relate with ganglionar metastases which is 
associated with poorer patient OS and cancer-dependent death. 
Today's available chemotherapy regimens (Cisplatin-based) and guidelines for 
BC management lack better options. Patients who undergo chemotherapy must 
have a T3 or T4 staged tumour or a T2 tumour with loco-regional disease 
(ganglionar metastization) (Gakis et al., 2013). However, most of MIBC patients are 
elderly and present several co-morbidities which preclude the treatment. Aiming to 
understand if STn relates with patient outcome of those who were submitted to CG 
regimens (Cisplatin and Gemcitabine regimens), patient OS was compared for those 
with STn positive and negative primary tumours. Results indicate that no 
association was found between these two groups (p= 0,654, see Figure 8), 
indicating that STn might not be a good biomarker for treatment outcome 
prediction.  
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Still aiming to assess the extent of STn presence in advanced disease, 23 
metastases and 8 related primary tumours were analysed. STn staining was present 
both in the primary tumour and its metastasis (p=0,267, data not shown). However, 
due to the small number of corresponding primary tumours no conclusion could be 
reached about STn behaviour in the primary tumours and the corresponding 
metastasis; prevailing the question about STn maintenance when cells migrate from 
the primary to form metastases. Finally and for the first time, it was found that STn 
is present in the metastases and tend to be associated with a poor patient OS 
(p=0,169, see Figure 9); however further studies must be performed in a larger 
dataset to fully disclose this relationship. 
 
Figure 8 - Association between STn immunoreactivity in patients treated with Cisplatin-
based chemotherapy regimens and their OS. Kaplan-Meier analysis was used to assess the 
association between STn labeling and the OS of patients that underwent Cisplatin and Gemcitabine 
chemotherapy regimens. STn -, STn negative cases; STn +, STn positive cases. 
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Figure 9 - Association between STn immunoreactivity in patients with metastatic disease 
and their OS. Kaplan-Meier analysis was used to assess the relation between STn labeling and the OS 
of patients with metastatic disease. STn -, STn negative cases; STn +, STn positive cases. 
For the first time, it was observed that more advanced tumor presenting 
ganglionar metastization is prone to express STn in the primary tumor and in the 
metastasis’ front of invasion. Furthermore, STn is thought to prevail in metastases 
that derivate from STn positive primary tumors. Hence, these findings indicate that 
STn may constitute a suitable biomarker to predict ganglionar and distant 
metastization. 
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6.3. Gene expression in T24 cultured cells  
Due to the possible influence and biomarker role of STn antigen described in 
this work, it was important to understand the association between Cisplatin 
resistance, stem and mesenchymal phenotypes and STn expression. Stem and 
mesenchymal phenotypes are known to relate with increased tumour 
aggressiveness and reproduction upon xenotransplantation (Bernardo et al., 2014), 
enlighten by colony formation and tumour features reproduction in vitro and in vivo 
assays, respectively. Furthermore, several CSC related genes (Celià-terrassa et al., 
2012) were found to be over-expressed in Cisplatin resistant cells in in vitro 
studies. Upon understanding that tumour aggressiveness and CSC-like phenotype 
are actually related and that STn is overexpressed in advanced tumours, which tend 
to migrate and develop local and distant metastasis; one set out to understand if 
cells submitted to Cisplatin treatment express these phenotypes and, if so, if STn is 
present in those cells. T24 cells treated with Cisplatin presented an over-expression 
of 10 of the 21 tested genes. These cells had elevated transcription levels of 
EPCAM, KLF4 and 9, CDH2 (N-cadherin), ZEB1, RUNX2, POU5F1 (Oct4), FN1, SPARC 
and LIN28A (see Figure 10).  As demonstrated in Figure 10, LIN28A and SPARC 
showed the most significant fold of increase in the gene panel. 
(A)  (B)  
Figure 10 - Transcript levels of over-expressed genes. (A) Graphical comparison of different 
transcript levels. (B) Fold increase for each analyzed gene.  
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LIN28A controls cellular reprogramming and pluripotency via miRNA 
regulation and is frequently found up-regulated in various types of cancer other 
than bladder (Li et al., 2013) and in CSCs. It is responsible for cell shape alteration, 
proliferation, colony formation and matrix invasion (Faria et al., 2014; Hayashi et 
al., 2013; Mao et al., 2013). SPARC encodes for a cysteine-rich acidic matrix-
associated protein that modulates interactions between tumor cells and the 
involving stroma (Nakashima et al., 2014). It has been found over-expressed in a 
series of tumors, such as bladder cancer (Millis et al., 2014; Yamanaka et al., 2001) 
- in which was linked to tumor progression and aggressiveness-, biliary tract 
(Nakashima et al., 2014) and melanoma (Botti et al., 2014). SPARC over-expression 
has also been related with Cisplatin resistance (Jeung et al., 2011; Pannuru et al., 
2014) and CSC prevalence (Choi et al., 2013; Yusuf et al., 2014). The remain over-
expressed genes, KLF4 and 9 and POU5F1, CDH2 and FN1, and ZEB1 and RUNX2 
(see Table 6) for further understanding of these genes cellular functions) are 
responsible for the activation of a series of genetic programs that predispose cells 
to a more aggressive phenotype. Comparing mesenchymal and epithelial markers 
(see Figure 10) it seems that there is a tendency for these cells to route towards the 
mesenchymal phenotype; and analyzing SNAI1, RUNX2, ZEB1 and 2 transcript levels 
it is clear that T24 cells treated with Cisplatin tend to express EMT program 
activation genes. 
Altogether these results indicate that treatment with Cisplatin may act as a 
selector of more resistant clones, as suggested by other authors (Barr et al., 2013; 
Hayashi et al., 2013; Richard et al., 2013). Also, it is possible that Cisplatin it-self 
induces DNA mutations that prepare cells to resist to treatment and to conceal in 
the quiescent state. In this case T24 bladder cancer cells presented a clear EMT 
program activation and an over-expression of genes that regulate cellular 
pluripotency and stromal constitution, all characteristics present in phenotypically 
aggressive tumors and cells lines (Barr et al., 2013; L. Li et al., 2012; van der Horst 
et al., 2012).  
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Table 6 - Resume of cellular function of the up-regulated genes in its pathological context.  
Cellular functions of the up-regulated genes 
Gene Function 
EpCAM 
Codes for a homotypic calcium-independent adhesion molecule that is normally expressed in normal epithelial cells 
and gastrointestinal carcinomas (Battista et al., 2014). 
KLF4 and 9 
Members of the KLF family of transcription factors. These genes encode for transcription factors responsible for 
regulating cell proliferation, differentiation and apoptosis (Krstic et al., 2013).  
POU5F1  
Also known as Oct-4, codes for a homeodomain transcription factor that belongs to the POU family. This protein is 
essential for self-renewal of undifferentiated embryonic stem cells and is frequently used as a marker for the presence 
of undifferentiated cells (S. C. Tsai et al., 2014). 
CDH2 
The encoded protein belongs to the cadherin superfamily and is a calcium-dependent cell-cell adhesion glycoprotein. 
It is frequently associated with acquired mesenchymal phenotype in cancer cells and is present in EMT program 
activation (Zhang et al., 2013). 
FN1 
Encodes for the glycoprotein fibronectin present in plasma, cell surface and extracellular matrix. It is involved in cell 
adhesion and migration processes and is commonly associated with metastization (Celià-terrassa et al., 2012). 
ZEB1 
Encodes for a zinc finger transcription factor and is responsible for repressing interleukin 2 transcription, being 
normally found over-expressed in cancer cells (Bronsert et al., 2014). 
RUNX2 
Encodes for a Runt DNA-binding domain and belong to the RUNX family of transcription factors. RUNX2 regulates the 
expression of genes associated with tumor progression, invasion and metastization. It is also associated with VEGF 
induction and of another major pro-angiogenic factor, hypoxia-inducible factor 1-α (HIF1-α) (Boregowda et al., 2014). 
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Nevertheless, this study's design may be further improved in order to better 
understand the role of Cisplatin exposure in CSC selection. It would be of interest to 
evaluate possible alterations in a series of periodic treatments with Cisplatin with 
smaller recovery periods (see Figure 11). This new study design would comprise a 
first stage of cell sorting through Fluorescence-Activated Cell Sorting (FACS) 
Cytometry for STn. The gene expression pattern of the STn positive and negative 
cells would be separately characterized before initiating the assay; and the exposed 
arm of the assay would comprise a pool of STn positive and a pool of STn negative 
cells, cultured and treated in separate. Other authors normally choose to expose 
cells to a higher dose of load for a shorter period of time (Yi Zhang, Zhi Wang , Jin 
Yu, Jia zhong Shi, Chu Wang, Wei hua Fu, Zhi wen Chen, 2012). However, the actual 
schedule of Cisplatin-based regimens is every 15 days, allowing patient – and tumor 
– to recover from the previous Cisplatin dose. Exposing cells to Cisplatin as 
explained and presented in Figure 11 would better mimic the normal treatment 
course.   
 
Figure 11 – Improved assay design. FACS – Fluorescence-Activated Cell Sorting. 
 
6.4. Sialyl-Tn is present in T24 cells exposed to Cisplatin 
As described, STn is present in more advanced and aggressive tumors. 
Furthermore it was able to establish that T24 cells submitted to Cisplatin presented 
stem- and mesenchymal-like phenotypes and increased expression of EMT program 
genes which correspond to in vivo tumors with a higher likelihood for progression, 
migration and metastization. Moreover, STn expression was evaluated to validate 
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the presence of this antigen in the chemoresistant clones. Optical density was 
measured and protein normalized results for Actinβ calculated (see Figure 12). No 
difference was found between the expression of STn in the two groups (p=0,125) 
which suggests that STn is both present in exposed and non-exposed cells; and that 
the exposed cells that resist to Cisplatin treatment express STn. 
 
Figure 12 - STn expression in T24 cells exposed to Cisplatin. STn antigen normalized Optical 
Density (OD) for Actinβ. No significant difference was found between the two groups for STn 
expression. 
Herein, it is described for the first time, that STn is present in cells that resist 
to treatment with Cisplatin which are known to have with a more aggressive 
phenotype. Since STn is not significantly expressed in other tissues and in normal 
urothelium it may be a suitable marker for guided therapies which would improve 
drug delivery and reduce side-effects. Nevertheless, more exploratory data is 
needed.   It is also necessary to evaluate, with the new study design presented, if 
the STn positive cells have an improved capacity for resisting Cisplatin and if they 
tend to be more invasive – through invasion assays – than the STn negative cells. 
Moreover, it would be of interest to understand if these STn positive cells that resist 
to Cisplatin are able to reproduce tumor’s heterogeneity in vivo. Furthermore, it is 
important to unveil the proteins which STn is linked through MALDI-TOF Mass 
Spectrometry. Therefore, glycosylation is a regulatory post-translational alteration 
and might be responsible for the activation or inhibition of some signaling 
pathways that interfere with Cisplatin cytotoxicity. 
31,2 
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7. Conclusions and future perspectives 
Cisplatin's treatment main disadvantages are tumor resistance to treatment 
and dose-dependent side-effects. For the first time, it has been reported that more 
advanced tumors tend to express STn and that ganglionar and distant metastases 
also express this antigen. Furthermore, for the first time it was possible to relate a 
CSC-like phenotype with STn expression. Taken in account these results, STn could 
be a good target for novel targeted therapies and as disease progression biomarker 
that should be investigated. Recent reports has highlighted that nano-encapsulated 
drugs may be a good approach to overcome chemotherapy resistance (Gryparis, 
Mattheolabakis, Bikiaris, & Avgoustakis, 2007; Iinuma et al., 2002), moreover active 
targeting nanocomplexes directed to structures such as STn, may help to improve 
this approach.  
Taken together the improvements suggested in the previous section, as future 
perspectives is important to introduce improvements in assay design of the in vitro 
experiment and adding FACS cytometry to previously select STn positive cells and 
identify the proteins carrying the STn antigen, Thus it is expected to better 
understand the STn role in the development of chemoresistance to Cisplatin 
treatment. 
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